Can Vyriad’s VV169 redefine CAR T therapy with single-dose in vivo delivery?
Vyriad secures $85M to launch VV169, its in vivo CAR T therapy for multiple myeloma. Find out how this platform could reshape cancer immunotherapy.
Can Cataltheia’s Deseyne lens replace multifocal optics in age-related vision correction?
FDA clears Deseyne, the first EDOF contact lens for presbyopia. Find out how it could reshape non-surgical vision correction in the U.S. market.
Janux Therapeutics advances masked EGFR T cell engager JANX008 into Phase 1 expansion
Janux Therapeutics pushes JANX008 into Phase 1 expansion across EGFR+ cancers. Discover how masking technology may shift the immunotherapy safety paradigm.
Gilead Sciences acquires RP-3467 from Repare Therapeutics in $30m synthetic lethality deal
Gilead Sciences acquires Repare’s RP-3467 Polθ inhibitor for up to $30M. Find out what this means for BRCA-targeted therapy and synthetic lethality M&A.
Omeros secures FDA approval for YARTEMLEA, the first therapy for transplant-associated TA-TMA
FDA approves YARTEMLEA for TA-TMA. Find out how Omeros’ new drug could change transplant care for children and adults alike.
Can epigenome editing bypass gene size limits? Modalis’ LAMA1 data revives hope in congenital muscular dystrophy
Modalis unveils primate data showing safe LAMA1 gene activation for LAMA2-CMD. Find out what it means for CRISPR therapeutics and CMD patients.
QurAlis links QRL-101 to motor nerve excitability shift in ALS: Is target validation finally here?
QurAlis confirms target engagement of QRL-101 in ALS patients. Find out what this means for epilepsy trials and Kv7-targeted drug development.
Can Johnson & Johnson’s RIPTAC bet deliver the next wave of targeted oral cancer drugs?
Johnson & Johnson’s $3B Halda acquisition brings RIPTACs into focus. Find out what it means for prostate cancer therapy and precision oncology.
Can Establishment Labs shift the breast reconstruction standard in the U.S. with Motiva?
Find out how Establishment Labs is aiming to transform U.S. breast reconstruction with Motiva implants and FDA approval. Read what changes and risks lie ahead.
Genmab ends acasunlimab trials: What it signals about bispecific immunotherapy risk
Genmab ends development of acasunlimab to focus on EPKINLY, petosemtamab, and Rina-S. Find out what this shift means for 4-1BB bispecifics today.